Intellia Therapeutics, Inc.
NTLA
$13.36
-$0.12-0.89%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -412.69M | -445.81M | -480.19M | -525.91M | -519.02M |
| Total Depreciation and Amortization | 15.92M | 12.47M | 10.15M | 10.27M | 10.29M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 75.79M | 94.89M | 118.14M | 155.67M | 147.98M |
| Change in Net Operating Assets | -73.75M | -72.21M | -66.67M | -17.18M | 11.88M |
| Cash from Operations | -394.74M | -410.65M | -418.58M | -377.15M | -348.88M |
| Capital Expenditure | -1.13M | -1.98M | -3.23M | -4.01M | -5.78M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 229.16M | 354.05M | 348.33M | 218.00M | 131.35M |
| Cash from Investing | 228.03M | 352.06M | 345.09M | 213.99M | 125.57M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 131.49M | 131.83M | 99.16M | 125.76M | 185.75M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 131.49M | 131.83M | 99.16M | 125.76M | 185.75M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -35.22M | 73.24M | 25.67M | -37.40M | -37.57M |